Meeting
2023 ASCO Annual Meeting
Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma.
Presenter
Sujay A. Vora, MD
Mayo Clinic Arizona
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03778294
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2002)
DOI
10.1200/JCO.2023.41.16_suppl.2002
Abstract #
2002
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study.
Speaker: Antoine F Carpentier
Videos & Slides
2022 ASCO Annual Meeting
Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).
Speaker: Walid Macaron, MD MSc
Videos & Slides
2021 ASCO Annual Meeting
Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.
Speaker: Rifaquat Rahman, MD
Speaker: Barbara Burtness, MD